Health Condition 1: J45- Asthma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: i. Age between 12-21 years(adolescent) and 21-65 years. ii. Patients of either sex or transgender iii. Patients with asthma (ICD -11 code CA23) are confirmed by the following criteria- HISTORY OF TYPICAL VARIABLE RESPIRATORY SYMPTOMS: Wheeze, shortness of breath, chest tightness and cough (Descriptors may vary between cultures and by age). Symptoms or features that support the diagnosis of asthma- ? More than one type of respiratory symptom (in adults, isolated cough is seldom due to asthma) ? Symptoms occur variably over time and vary in intensity ? Symptoms are often worse at night or on waking ? Symptoms are often triggered by exercise, laughter, allergens, cold air ? Symptoms often appear or worsen with viral infections CONFIRMED VARIABLE EXPIRATORY AIRFLOW LIMITATION: Documented excessive variability in lung function (one or more of the following): The greater the variations, or the more occasions excess variation is seen, the more confident the diagnosis. If initially negative, tests can be repeated during symptoms or in the early morning. Positive bronchodilator (BD) responsiveness (reversibility): Adults: increase in FEV1 of greater than 12% and 200 ml. (greater confidence if the increase is greater than 15% and greater than 400 mL). Measure change 10-15 minutes after 200-400 mcg salbutamol (albuterol) or equivalent. ? Excessive variability in twice-daily PEF over 2 weeks: Adults average daily diurnal PEF variability greater than 10%. Documented expiratory airflow limitation: At a time FEV1 is reduced (e.g. during testing above), confirmed that FEV1/FVC is also reduced compared with the lower limit of normal (it is usually greater than 0.75-0.80 in adults). iv. Indication of Morgan pure- ? History of pneumonia or bronchopneumonia; never well since. Bronchitis and asthma(self-reported) ? At least 3 important symptoms from the symptomatology of Morgan pure. ? Differentiation and comparison with other drugs with the help of the literature. ? Individualization of the case to be ratified by consensus among three prescribers.
Exclusion criteria
Exclusion criteria: i. Known lower respiratory tract disease other than asthma. ii. Not providing written informed consent and/or assent voluntarily to participate in the study. iii. ICD-11 code- allergic asthma with status asthmaticus (CA23.01), non-allergic asthma, with status asthmaticus (CA23.11), aspirin-induced asthma (CA23.20), unspecified asthma with status asthmaticus (CA23.31). iv. Severe persistent asthma (FEV1 less than 60%) v. Need for immediate ICU care vi. Diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life-threatening illness affecting the quality of life or any organ failure. vii. Tobacco chewing and/or smoking, alcoholism and/or any other form(s)of substance abuse and/or dependence. viii. Self-reported immune-compromised state. ix. Already undergoing homoeopathic treatment for chronic diseases other than asthma within the last 1month. x. Simultaneous participation in any other clinical trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Asthma Control Test(ACT) scoreTimepoint: Baseline, every 17 days, up to 102 days | — |
Secondary
| Measure | Time frame |
|---|---|
| AQLQ(S)-(Asthma Quality of Life Questionnaire for 12 years and older)Timepoint: Baseline, every 17 days, up to 102 days;Measure Yourself Medical Outcome Profile, version 2.0 (MYMOP-2)Timepoint: Baseline, every 17 days, up to 102 days;Spirometry measures: FEV1 (Forced Expiratory Volume in 1 second), FVC (Forced vital capacity), FEV1/FVC and PEF (Peak Expiratory Flow)Timepoint: Baseline, every 17 days, up to 102 days | — |
Countries
India
Contacts
D. N. De Homoeopathic Medical College and Hospital